Michelle Polan, MD
Clinical Genetics (M.D.) · Tulsa, OKNPI 1689835209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,718 of the $2,630 with a category attached, or 65.3%. 23 manufacturers reported payments, led by Amgen at 28.9% of the total. Reporting peaked in 2020 at $991 and has fallen 84.3% since, to $155 in 2023.
Across 95 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$760
- Biomarin Pharmaceutical Inc.$350
- Sanofi$265
- Eisai Inc.$241
- Amicus Therapeutics, Inc.$159
- Sunovion Pharmaceuticals Inc.$121
- plus $734 from 17 others
What the payments were for
- Speaking & faculty fees$76029%
- Food & beverage$1,71865%
- Education$1526%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $760 |
| Biomarin Pharmaceutical Inc. | 16 | $350 |
| Sanofi | 7 | $265 |
| Eisai Inc. | 14 | $241 |
| Amicus Therapeutics, Inc. | 6 | $159 |
| Sunovion Pharmaceuticals Inc. | 9 | $121 |
| AstraZeneca | 6 | $114 |
| Livanova USA, Inc. | 4 | $97 |
| UCB, Inc. | 5 | $76 |
| Amneal Pharmaceuticals LLC | 5 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $57 |
| PTC Therapeutics, Inc. | 2 | $47 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Aquestive Therapeutics, Inc. | 2 | $37 |
| Biogen | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $32 |
| Vanda Pharmaceuticals Inc. | 2 | $29 |
| Duchesnay USA Incorporated | 1 | $23 |
| Greenwich Biosciences, Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| NS Pharma, Inc. | 1 | $15 |
| Rhodes Pharmaceuticals L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAVICTI$760
- DISEASE STATE$123
How this compares
Too few clinical genetics (m.d.) providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other clinical genetics (m.d.) in Tulsa
- Mauricio de Castro PreteltOklahoma City$2K
- Danielle DemarzoOklahoma City$1K
- Yazmin Enchautegui ColonOklahoma City$526
- Chelsie HollasBethany$319
- Marsha PrattOklahoma City$163
- Susan PalmerOklahoma City$23
- John MulvihillOklahoma City$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.